Pilot Study to Assess the Effect of High Dose N-acetylcysteine (NAC) in Chronic Obstructive Pulmonary Disease (COPD) Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00969904 |
Recruitment Status
:
Completed
First Posted
: September 1, 2009
Last Update Posted
: July 3, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Studies suggest that N-acetylcysteine (NAC) potentially reduces inflammation and hyperinflation in patients with COPD.
In this pilot study the efficacy, safety and tolerability of high dose NAC in 12 patients with moderate COPD will be examined. These patients will receive a placebo for 12 weeks and NAC for 12 weeks in a dosage of 3 times 600 mg a day on top of their usual medication in a randomized crossover design. All subjects will be followed for 28 weeks.
The effect of high dose NAC on small airways will be assessed by measuring the total and peripheral airway resistance calculated with Computational Fluid Dynamics (CFD). The effect on oxidative stress will be assessed by measuring exhaled NO and specific markers (CRP, erythrocyte sedimentation rate, IL-6, 8-isoprostane, H2O2, TNF-alfa, glutathione, GPX, SOD and IL-8) in blood and Exhaled Breath Condensate (EBC). Dynamic and static lung volumes will be assessed by spirometry, body plethysmography and diffusion. Quality of life and symptoms will be assessed by the St George Respiratory Questionnaire.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
COPD | Drug: N-acetylcysteine Drug: placebo | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 12 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Double Blind, Randomized, Placebo-controlled, Two-way Crossover, Pilot Study to Assess the Effect of High Dose N-acetylcysteine on Small Airways and on Inflammation and Oxidative Stress in COPD Patients. |
Study Start Date : | March 2009 |
Actual Primary Completion Date : | January 2011 |
Actual Study Completion Date : | January 2011 |

Arm | Intervention/treatment |
---|---|
Active Comparator: 1 |
Drug: N-acetylcysteine
600 mg TID for 12 weeks
|
Placebo Comparator: 2 |
Drug: placebo
placebo tablet TID for 12 weeks
|
- To assess the effect of high dose NAC (1800 mg)on small airways by measuring the total and peripheral airway resistance calculated with CFD [ Time Frame: at baseline, after 12 weeks of placebo and after 12 weeks of NAC ]
- To assess the effect of high dose NAC (1800 mg)on oxidative stress by measuring exhaled NO and oxidative stress markers in blood and EBC [ Time Frame: at baseline, after 12 weeks of placebo and after 12 weeks of NAC. ]
- To assess dynamic and static lung volumes by spirometry, body plethysmography and diffusion [ Time Frame: will be assessed at all visits ]
- To assess quality of life by the SGRQ [ Time Frame: will be assessed at all visits ]
- To assess the tolerability and safety of high dose NAC [ Time Frame: all visits ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Patients with documented COPD based on the following criteria:
- Smoking history of at least 10 pack-years
- Decreased Tiffeneau index (FEV1/(FVC < 0.70)
- Patients aged ≥ 40 years
- Patients who stopped smoking since more than 1 month
- Patients who present moderate COPD with an FEV1 between 50 and 80% of predicted (GOLD 2)
- Patients should be treated according to GOLD guidelines
Exclusion Criteria:
- Unstable patients who developed an exacerbation during the last 8 weeks
- Patients who are current smokers or stopped less than 1 month
- Patients who are allergic to acetylcysteine or to another element of the product
- Patients with phenylketonuria or an untreated active peptic ulcer
- Patients with any stage kidney and/or heart insufficiency or hypertension
- Patients already treated with NAC for more than 6 months or during the last 3 months
- Patients on continuous treatment with oral, inhalation, intravenous or intramuscular corticosteroids
- Patients who are pregnant or are breast-feeding
- Patients who are treated with orally administered cephalosporins
- Patients using supplements containing antioxidants as vitamins C or E

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00969904
Belgium | |
University Hospital Antwerp | |
Edegem, Antwerp, Belgium, 2650 |
Principal Investigator: | Wilfried A De Backer, MD, PhD | University Hospital, Antwerp |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Wilfried De Backer, MD PhD, University Hospital, Antwerp |
ClinicalTrials.gov Identifier: | NCT00969904 History of Changes |
Other Study ID Numbers: |
PML_DOC_0804 EC 8/40/128 |
First Posted: | September 1, 2009 Key Record Dates |
Last Update Posted: | July 3, 2012 |
Last Verified: | June 2012 |
Additional relevant MeSH terms:
Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive Lung Diseases Respiratory Tract Diseases Acetylcysteine N-monoacetylcystine Antiviral Agents Anti-Infective Agents |
Expectorants Respiratory System Agents Free Radical Scavengers Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Antidotes |